POMC and obesity due to melanocortin 4 receptor deficiency: Accordingly, the only available anti-obesity drug directly targeting opioid pathways is a combination of naloxone/bupropion, which blocks central beta-endorphin messaging and leads to stimulation of anorexigenic pathways [75, 76].